Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Side effects of GLP-1s: weighing the risks and rewards. Employers Health. https://www.employershealthco.com/resource-center/articles/side-effects-of-glp-1s-weighing-the-risks-and-rewards/. Accessed February 25, 2025.

Rizvi

Rizzo

. The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction. Diabetes Metab Syndr Obes. 2022;15:1023-1030. doi:10.2147/DMSO.S351982

Mahase

. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024;386:q1645. doi:10.1136/bmj.q1645

Capoot AKC Ashley . Healthy returns: more U.S. employers are now covering GLP-1s for weight loss. CNBC. June 18, 2024. https://www.cnbc.com/2024/06/18/healthy-returns-more-us-employers-covering-glp-1s-for-weight-loss.html. Accessed February 25, 2025.

Eberly

Yang

Essien

, et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. doi:10.1001/jamahealthforum.2021.4182

Disparities in the use of new diabetes medications: widening treatment inequality by race and insurance coverage. doi:10.26099/vabp-0g69

Limonte

Hall

Trikudanathan

, et al. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabet Complicat. 2022;36(6):108204. doi:10.1016/j.jdiacomp.2022.108204

Cromer

Lauffenburger

Levin

Patorno

. Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among medicare-insured adults following a new diagnosis of cardiovascular disease or heart failure. Diabetes Care. 2022;46(1):65-74. doi:10.2337/dc22-0383

Chen

Yang

, et al. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes. PLoS One. 2024;19(1):e0297208. doi:10.1371/journal.pone.0297208

10.

Lamprea-Montealegre

Madden

Tummalapalli

, et al. Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the veterans health administration system. JAMA. 2022;328(9):861-871. doi:10.1001/jama.2022.13885

11.

Team gacapus . The impact of healthcare policies on GLP-1 medications. Georgia CAPUS Resource Hub. August 20, 2024. https://www.gacapus.com/impact-of-healthcare-policies-on-glp-1-medications/. Accessed February 25, 2025.

12.

GLP-1 medication access limited by care site, payer type, demographics. https://www.healio.com/news/endocrinology/20241105/glp1-medication-access-limited-by-care-site-payer-type-demographics. Accessed February 25, 2025.

13.

Employer coverage of GLP-1 weight loss drugs expected to double. Healthcare Finance News. https://www.healthcarefinancenews.com/news/employer-coverage-glp-1-weight-loss-drugs-expected-double. Accessed February 25, 2025.

14.

McMullin

. Employer coverage of GLP-1 drugs on the rise. Word on Benefits. June 13, 2024. https://blog.ifebp.org/employer-coverage-of-glp-1-drugs-on-the-rise/. Accessed February 25, 2025.

15.

Health care costs are frightening employers—but these strategies can make them less scary. https://www.shrm.org/topics-tools/news/benefits-compensation/health-care-costs-are-frightening-employers-but-these-strategies. Accessed February 25, 2025.

16.

As Interest in GLP-1 Drugs Spikes . Employers weigh the costs, benefits | WorldatWork. https://worldatwork.org/publications/workspan-daily/as-interest-in-glp-1-drugs-spikes-employers-weigh-the-costs-benefits. Accessed February 25, 2025.

17.

Newman

. The decision to cover GLP-1s is a culture one: balancing health, finance and values. Corporate Synergies. January 21, 2025. https://www.corpsyn.com/knowledge-center/glp-1-coverage/. Accessed February 25, 2025.

18.

Team

. GLP-1 medications and employer health plans: what you need to know. SBMA Benefits. December 22, 2024. https://www.sbmabenefits.com/glp-1-medications-and-employer-health-plans-what-you-need-to-know/. Accessed February 25, 2025.

19.

GLP-1 drugs: implications for employer health plans. WTW. https://www.wtwco.com/en-us/insights/2024/02/glp-1-drugs-implications-for-employer-health-plans. Accessed February 25, 2025.

20.

Bluebook

. Employer’s guide to integrating GLP-1s into health benefits packages. https://blog.healthcarebluebook.com/employers-guide-to-integrating-glp-1s-into-health-benefits-packages. Accessed February 25, 2025.

21.

James

. Lifestyle changes to lower heart disease risk. Harvard Health. November 2, 2019. https://www.health.harvard.edu/blog/lifestyle-changes-to-lower-heart-disease-risk-2019110218125. Accessed February 25, 2025.

22.

Zhang

Xia

, et al. Influencing factors and implementation pathways of adherence behavior in intelligent personalized exercise prescription: qualitative study. JMIR MHealth UHealth. 2024;12:e59610. doi:10.2196/59610

23.

Whitsel

Ablah

Pronk

, et al. Physical activity promotion in the evolving work landscape. Am J Health Promot. 2023;37(5):723-730. doi:10.1177/08901171231172013b

24.

Das

Mailey

Murray

Phillips

Torres

King

. From sedentary to active: shifting the movement paradigm in workplaces. Work Read Mass. 2016;54(2):481-487. doi:10.3233/WOR-162330

25.

CDC . Workplace health promotion. August 1, 2024. https://www.cdc.gov/workplace-health-promotion/php/index.html. Accessed February 25, 2025.

26.

Neeland

Linge

Birkenfeld

. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. doi:10.1111/dom.15728

27.

Jensen

SBK

Blond

Sandsdal

, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. 2024;69:102475. doi:10.1016/j.eclinm.2024.102475

28.

How much protein do you need to eat per day to lose weight? - NASM. https://blog.nasm.org/nutrition/how-much-protein-should-you-eat-per-day-for-weight-loss. Accessed February 25, 2025.

29.

Stanford

. The importance of diversity and inclusion in the healthcare workforce. J Natl Med Assoc. 2020;112(3):247-249. doi:10.1016/j.jnma.2020.03.014

30.

Johnson

. A rationale and framework for activating employers as agents of change in the implementation of lifestyle as medicine. Am J Health Promot. 2023;37(7):997-1013. doi:10.1177/08901171231184527a

31.

Grants – HERO. https://hero-health.org/research/grants/. Accessed March 28, 2025.

Access to GLP-1s: Where Do Employers Fit in?

Abstract

Get full access to this article

References